Ativisha: Traditional Uses, Evidence & Safety

Q: Is ativisha the same as aconite?

No, but they are close relatives. Ativisha is Aconitum heterophyllum, one species inside the aconite genus. A 2022 review calls it the only nonpoisonous member of that genus, because its main alkaloids are atisinetype compounds, far less toxic than the aconitine that makes other aconites lethal (Wani et al., J Integr Med 2022). Most other aconites are highly toxic, so only use authenticated, tested material from reputable sources.

Q: If it is the "nonpoisonous" aconite, is it safe to take?

"Nonpoisonous" is comparative, not a guarantee. It means the plant's own alkaloids (atisine, hetisine and related compounds) are far less toxic than aconitine, the poison in other aconites (Indian Medicinal Plants database). It does not mean safe at any dose, in any person, from any supplier. The realworld danger is adulteration with genuinely toxic aconite roots, which look similar once dried and powdered. Authentication matters more than the species' reputation.

Q: What is ativisha used for in children?

In Ayurveda, ativisha is a key ingredient of Balchaturbhadra Churna, a classical fourherb pediatric formula indicated in classical texts for fever, cough, and diarrhea in children (Choudhary et al., AYU 2022). That is a traditional indication, not clinical proof. The only human study found tested the whole formulation in 40 children with diarrhea, so there is no clinical evidence that ativisha by itself helps childhood illness (Mane, Int J Indian Med 2021).

Q: Does research support ativisha for diarrhea?

Only weakly, and only as part of a formula. In a 2021 randomized openlabel trial, 40 children aged 5 to 14 received either Balchaturbhadra Yoga (containing ativisha) or Pathadi Churna for 7 days; both groups improved significantly on stool measures, with the ativishacontaining formula slightly ahead on some outcomes (Mane, Int J Indian Med 2021). No placebo group, small sample, short duration, and ativisha never tested alone. That is weak evidence, not proof.

Q: What dose does the Ayurvedic Pharmacopoeia give for ativisha?

The Ayurvedic Pharmacopoeia of India (Vol. I) gives a root dose of 0.6 to 2.08 g, a monograph figure for the dried root rather than a clinical recommendation (Indian Medicinal Plants database). The one published trial dosed children by Young's formula, an agebased fraction of the adult dose. There is no established modern clinical dose, and none for pregnancy, breastfeeding, or longterm use.

Q: Is ativisha endangered?

Yes. A 2022 review in the Journal of Integrative Medicine describes Aconitum heterophyllum as a critically endangered medicinal herb of the northwestern Himalayas (Wani et al., J Integr Med 2022). This matters twice over. Ecologically, wild harvesting threatens the species. Practically, scarcity raises the risk of substitution with other, potentially toxic aconite roots. Prefer cultivated, tested, traceable material.

TL;DR

Ativisha is the tuberous root of Aconitum heterophyllum, a critically endangered Himalayan aconite and Ayurveda's pediatric digestive herb. Its alkaloids are far less toxic than aconitine, but no human trial of the root alone exists; the only clinical data come from one small trial of a four-herb formula. Identity fraud with toxic aconites is the main danger.

What it is

Ativisha is the dried tuberous root of Aconitum heterophyllum Wall. ex Royle, a Himalayan buttercup-family (Ranunculaceae) herb. In English it goes by "Indian Atees" or "Atis Root"; in folk use, "Patis" (Indian Medicinal Plants database).

A 2022 review in the Journal of Integrative Medicine makes the botanical identity worth stating twice. The species is a critically endangered medicinal herb of the northwestern Himalayas, harvested mostly for its roots, and it is "the only nonpoisonous member of the genus Aconitum" (Wani et al., J Integr Med 2022). Read that as comparative, not as a safety certificate. It sits inside a genus that contains some of the most poisonous plants on earth.

The plant grows at 2,000 to 4,000 m in the northwestern Himalayas, with cultivation recorded at Manali and Rahla in Himachal Pradesh (Indian Medicinal Plants database). The tuberous root is the used part. The published transcriptome of the species was sequenced from that same tuberous root (Malhotra et al., 3 Biotech 2016).

The chemistry explains the reputation. The root yields 0.79% total alkaloids, of which atisine is 0.4%, and atisine is described as much less toxic than aconitine and pseudoaconitine, the killers in other aconites (Indian Medicinal Plants database). A published UHPLC study identified and quantified eight alkaloids in the root as a quality-control tool (Wani et al., Phytochemical Analysis 2022 — publication record). Classical synonym lists read like a field guide: Shrungi, the horn-shaped tubers; Shuklakanda, the white tubers (Charak Samhita herb database).

Traditional use

Charaka's own herb database, maintained by the Charak Samhita Research, Training and Skill Development Centre, records ativisha for worms (krimiroga), fever (jvara), cough (kasa), vomiting (chhardi), and diarrhea (amatisara) (Charak Samhita herb database). Its Ayurvedic pharmacological profile is recorded as bitter and pungent taste (tikta, katu), hot potency (ushna virya), pungent post-digestive effect, light and rough qualities, reducing all three doshas (same database).

The classical references are specific. Charaka enrolls ativisha in the Lekhaniya mahakashaya, his group of herbs "for treatment of emaciation" (Sutra Sthana 4/9(3)) (Charak Samhita herb database). In the Apamarga Tanduliya chapter, he prescribes a gruel for diarrhea with ama: "gruel prepared with Ativisha (Aconitum heterophyllum Wall. ex Royle), Amla dadima (sour pomegranate) and Nagara (Zingiber officinale) is beneficial" (Apamarga Tanduliya Adhyaya, carakasamhitaonline.com). A published review reports that Sushruta places the drug in the Pippalyadi, Mustadi, and Vachadi ganas (IJCRT review). The Ayurvedic Pharmacopoeia of India, as indexed in the Indian Medicinal Plants database, indicates the dried tuberous root for emesis and helminthiasis (Indian Medicinal Plants database).

Ativisha is also one of the four ingredients of Balchaturbhadra Churna, "a polyherbal formulation mentioned in classical Ayurvedic texts specifically indicated for fever (Jvara), cough (Kasa), and diarrhea (Atisara) in children," alongside shringi (Pistacia integerrima), pippali (Piper longum), and musta (Cyperus rotundus) (Choudhary et al., AYU 2022).

These are traditional indications. I keep them in a separate box from the trial evidence for a reason.

What modern research says

Laboratory pharmacology (in-vitro evidence only)

The 2022 review's pharmacology section reads like a catalog: analgesic, anti-inflammatory, antiarrhythmic, antiparasitic, anticancer, and effects on the central nervous system. Nearly all of it comes from in-vitro experimental work (Wani et al., J Integr Med 2022). Laboratory findings are hypothesis-generating. They do not establish that ativisha treats any condition in people.

Childhood diarrhea: an ativisha-containing formulation (randomized open-label trial)

The only human trial found that includes ativisha tested it as part of a four-herb formula, not alone. In a 2021 randomized open-label study by Dr. Harshad Dattatray Mane at SDM Trust Ayurvedic Medical College, 40 children aged 5 to 14 with childhood diarrhea (balatisara) received either Balchaturbhadra Yoga (nagarmotha, ativisha, pippali, karkatashringi) or Pathadi Churna for 7 days, with doses set by Young's formula (Mane, Int J Indian Med 2021).

Both groups showed statistically highly significant within-group improvements in stool frequency, color, consistency, foul smell, and mucus (p<0.001). Between the groups, there was no significant difference on frequency, consistency, or mucus, while the Balchaturbhadra group did significantly better on stool color and foul smell (p<0.05). My honest read: no placebo or standard-care group, a small short trial at a single center, and ativisha's individual contribution cannot be isolated. Weak, formulation-level evidence. Not proof that ativisha works.

Toxicity signals (formulation-level, animal)

A 2022 AYU paper summarizing preclinical safety work on Balchaturbhadra Churna reports that an acute toxicity experiment produced no signs of toxicity up to 2000 mg/kg, while 900 mg/kg given for 45 days showed mild toxic potential (Choudhary et al., AYU 2022). These figures describe the four-herb formulation in animals, not ativisha alone, and cannot be translated into a human dose.

What the evidence does not support (yet)

No randomized human trial of ativisha alone was found in this review. There are no human studies of ativisha for fever, cough, worms, or vomiting. Claims about specific disease benefits therefore rest on traditional use and laboratory work, not on clinical evidence. Any product marketing ativisha with disease-treatment promises is going beyond what the evidence supports.

Dosage

The Ayurvedic Pharmacopoeia of India (Vol. I, as indexed by the Indian Medicinal Plants database) gives a root dose of 0.6 to 2.08 g (Indian Medicinal Plants database). That is a monograph figure for the dried root, not a prescription, and it says nothing about children, pregnancy, or long-term use. In the one published clinical trial, children's doses were set by Young's formula, an age-based fraction of the adult dose (Mane, Int J Indian Med 2021). Anyone who hands you a confident pediatric dose without citing either of these is improvising.

Safety & contraindications

Ativisha is described in a peer-reviewed 2022 review as the only nonpoisonous member of Aconitum (Wani et al., J Integr Med 2022). I treat that as a comparative chemical claim, not a permission slip. Its principal alkaloids, the atisine-type compounds, are far less toxic than aconitine, and the database's own monograph entry calls the plant "often regarded as nonpoisonous" (Indian Medicinal Plants database).

The context around that claim is what matters. In other aconites, the diester diterpenoid alkaloids are the killers: aconitine's toxic dose is about 0.2 mg and its lethal dose 2 to 4 mg, and poisoning brings numbness, nausea, vomiting, and cardiac arrhythmias through persistent activation of voltage-gated sodium channels (Frontiers in Pharmacology case report, 2024; PMC toxicology review of Aconitum). Ativisha's own genus membership is therefore the hazard. Misidentification or adulteration with other, toxic aconite species is the central safety concern, and the species' endangered status makes substitution more likely, not less. Buy only authenticated, tested material from reputable sources. Never wild-collected roots of uncertain identity.

Safety data in pregnancy and breastfeeding are essentially absent. I found no human study of ativisha in either group. Do not use it during pregnancy or while breastfeeding without direct guidance from a qualified clinician, and never as a substitute for standard medical care. The formulation-level animal data, mild toxic potential at prolonged high doses, underline that "traditional" does not mean "safe at any dose" (Choudhary et al., AYU 2022).

FAQs

Is ativisha the same as aconite?

No, but they are close relatives. Ativisha is Aconitum heterophyllum, one species inside the aconite genus. A 2022 review calls it the only nonpoisonous member of that genus, because its main alkaloids are atisine-type compounds, far less toxic than the aconitine that makes other aconites lethal (Wani et al., J Integr Med 2022). Most other aconites are highly toxic, so only use authenticated, tested material from reputable sources.

If it is the "nonpoisonous" aconite, is it safe to take?

"Nonpoisonous" is comparative, not a guarantee. It means the plant's own alkaloids (atisine, hetisine and related compounds) are far less toxic than aconitine, the poison in other aconites (Indian Medicinal Plants database). It does not mean safe at any dose, in any person, from any supplier. The real-world danger is adulteration with genuinely toxic aconite roots, which look similar once dried and powdered. Authentication matters more than the species' reputation.

What is ativisha used for in children?

In Ayurveda, ativisha is a key ingredient of Balchaturbhadra Churna, a classical four-herb pediatric formula indicated in classical texts for fever, cough, and diarrhea in children (Choudhary et al., AYU 2022). That is a traditional indication, not clinical proof. The only human study found tested the whole formulation in 40 children with diarrhea, so there is no clinical evidence that ativisha by itself helps childhood illness (Mane, Int J Indian Med 2021).

Does research support ativisha for diarrhea?

Only weakly, and only as part of a formula. In a 2021 randomized open-label trial, 40 children aged 5 to 14 received either Balchaturbhadra Yoga (containing ativisha) or Pathadi Churna for 7 days; both groups improved significantly on stool measures, with the ativisha-containing formula slightly ahead on some outcomes (Mane, Int J Indian Med 2021). No placebo group, small sample, short duration, and ativisha never tested alone. That is weak evidence, not proof.

What dose does the Ayurvedic Pharmacopoeia give for ativisha?

The Ayurvedic Pharmacopoeia of India (Vol. I) gives a root dose of 0.6 to 2.08 g, a monograph figure for the dried root rather than a clinical recommendation (Indian Medicinal Plants database). The one published trial dosed children by Young's formula, an age-based fraction of the adult dose. There is no established modern clinical dose, and none for pregnancy, breastfeeding, or long-term use.

Is ativisha endangered?

Yes. A 2022 review in the Journal of Integrative Medicine describes Aconitum heterophyllum as a critically endangered medicinal herb of the northwestern Himalayas (Wani et al., J Integr Med 2022). This matters twice over. Ecologically, wild harvesting threatens the species. Practically, scarcity raises the risk of substitution with other, potentially toxic aconite roots. Prefer cultivated, tested, traceable material.

Voices

The classical texts

Charaka knows ativisha well. His herb database, maintained by the Charak Samhita Research, Training and Skill Development Centre, records the drug for worms, fever, cough, vomiting, and diarrhea, and enrolls it in the Lekhaniya mahakashaya, the group "for treatment of emaciation" (Sutra Sthana 4/9(3)) (Charak Samhita herb database). The most concrete classical prescription I found sits in the Apamarga Tanduliya chapter: for diarrhea with ama, "gruel prepared with Ativisha (Aconitum heterophyllum Wall. ex Royle), Amla dadima (sour pomegranate) and Nagara (Zingiber officinale) is beneficial" (Apamarga Tanduliya Adhyaya). The synonym lists do the describing: Shrungi for the horn-shaped tubers, Shuklakanda for the white ones (Charak Samhita herb database).

The modern clinic

The closest thing ativisha has to a modern voice is a named investigator, not an anecdote. Dr. Harshad Dattatray Mane's 2021 trial at SDM Trust Ayurvedic Medical College tested Balchaturbhadra Yoga, a four-herb formula with ativisha, against Pathadi Churna in 40 children with diarrhea over 7 days. Both groups improved significantly; the ativisha-containing formula came out slightly ahead on stool color and foul smell (Int J Indian Med 2021). Small, single-center, no placebo group: interesting, not conclusive, and it says nothing about ativisha alone.

One caution I hold here: I found no published modern case reports of individual practitioners using ativisha, and no published interviews with vaidyas about it. The modern voice on this herb is a thin trial record, and I will not pad it with invented authority.

Sources

The botanical identity and the "only nonpoisonous member of the genus" claim rest on Wani TA, Kaloo ZA, Dangroo N, "Aconitum heterophyllum Wall. ex Royle: a critically endangered medicinal herb with rich potential for use in medicine," Journal of Integrative Medicine 20(2):104-113, 2022 (PubMed 34996731). Its abstract also supplies the in-vitro pharmacology catalog (analgesic, anti-inflammatory, antiarrhythmic, antiparasitic, anticancer, CNS effects) and the northwestern-Himalayan distribution. The Ayurvedic Pharmacopoeia of India (Vol. I) monograph is cited through the Indian Medicinal Plants database entry, which records the Sanskrit synonyms, the emesis and helminthiasis indications, the 0.79% total alkaloids with 0.4% atisine, the "much less toxic than aconitine and pseudoaconitine" comparison, and the 0.6-2.08 g root dose (link).

Classical-text references come from the Charak Samhita Research Centre's herb database (therapeutic uses, synonyms with glosses, rasa-virya-vipaka profile, Lekhaniya mahakashaya Su 4/9(3)) (link) and its Apamarga Tanduliya chapter translation (the ativisha gruel for diarrhea with ama) (link). The Sushruta gana placement is reported in a published IJCRT review of classical formulations in childhood respiratory disorders (link). The tuberous-root transcriptome is Malhotra N et al., "Transcriptome-wide mining suggests conglomerate of genes associated with tuberous root growth and development in Aconitum heterophyllum Wall.," 3 Biotech 6(2):152, 2016 (PMC4940232).

The alkaloid quantification study is Wani TA et al., "Identification and quantification of eight alkaloids in Aconitum heterophyllum using UHPLC-DAD-QTOF-IMS: A valuable tool for quality control," Phytochemical Analysis 33:1121-1134, 2022 (publication record). The childhood-diarrhea trial is Mane HD, "A comparative clinical study to evaluate the effect of Pathadi Churna and Balchaturbhadra Yoga in the management of Atisara w.s.r. to 'Bacterial Diarrhoea'," Int J Indian Med 2(10):7-17, 2021 (full text), the source of the 40-children, 7-day, p<0.001 figures. The Balchaturbhadra composition, classical pediatric indication (jvara, kasa, atisara), compound-level reported properties, and formulation toxicity figures (no acute signs to 2000 mg/kg; mild toxic potential at 900 mg/kg for 45 days) come from Choudhary K et al., "Balchaturbhadra Churna as a potential medicine for SARS-CoV2 infection in pediatric setting: An in silico study," AYU 43(4), 2022 (Ovid full text).

The aconitine toxicity context (toxic dose ~0.2 mg, lethal dose 2-4 mg, cardiac and neurological manifestations) is from a 2024 Frontiers in Pharmacology case report (link) and the sodium-channel mechanism from "The toxicology and detoxification of Aconitum: traditional and modern views" (PMC8314510).

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.